Form 4: Incyte EVP Lee Heeson Receives RSU Grant

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 8,911 restricted stock units, which will vest 25% annually over four years.

Summary

• Lee Heeson, EVP, Head of Incyte International, acquired 8,911 shares of Incyte Corp common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant was January 16, 2026.
• The RSUs were awarded at a price of $0 per unit, which is typical for equity grants.
• These RSUs are subject to a vesting schedule of 25% annually over a four-year period.
• Following this transaction, Lee Heeson beneficially owns an aggregate of 38,152 shares, which includes the new grant and previously reported unvested RSUs.
• The RSUs may be settled only for shares of common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: The grant of RSUs to a key executive is generally a neutral to slightly positive event, indicating continued alignment of management interests with shareholders, but does not reflect operational or financial performance.

Positives

• The grant of Restricted Stock Units (RSUs) to a key executive, Lee Heeson, aligns management's long-term interests with those of shareholders.
• RSUs are a common form of equity compensation designed to incentivize executive retention and performance.

Negatives

• The RSUs have no immediate cash value and are subject to a four-year vesting schedule, meaning the executive does not fully own the shares until the vesting conditions are met.
• The ultimate value of the compensation is tied directly to the future performance of Incyte's stock price, introducing market risk.

Risks

• The value of the RSU grant is subject to the future market price of Incyte common stock, which can fluctuate significantly.
• Vesting of the RSUs is contingent upon continued employment with Incyte Corp over the four-year period.
• Future changes in company performance or broader market conditions could reduce the ultimate value realized from these RSUs.

Future Outlook

The grant of Restricted Stock Units with a multi-year vesting schedule indicates an expectation of continued executive tenure and a long-term commitment to the company's performance.

Industry Context

Equity compensation, particularly through Restricted Stock Units (RSUs), is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. This grant is consistent with typical executive incentive structures seen across the sector.

Comparison to Industry Standards

• This RSU grant is a standard form of executive compensation, aligning with practices observed at comparable biotech and pharmaceutical companies.
• The four-year vesting schedule is also a common industry benchmark for long-term incentive plans, similar to those at companies like Amgen or Gilead Sciences, which use multi-year vesting to ensure executive retention and performance alignment.

Related Party Transactions

• The RSU grant represents an equity compensation transaction between the company and a key executive, which is a form of related party transaction.

Stakeholder Impact

• Shareholders: The grant aligns the executive's financial interests with long-term shareholder value creation, as the value of the RSUs is tied to the company's stock performance. It also results in minor dilution of existing shares upon vesting.
• Employees: This type of executive compensation can serve as a benchmark or motivator for other employees, demonstrating the company's commitment to performance-based incentives.

Next Steps

• The 8,911 Restricted Stock Units will vest 25% annually over the next four years, starting from the grant date of January 16, 2026.
• Upon vesting, the RSUs will be settled for shares of Incyte common stock on a one-for-one basis.

Key Dates

Keywords

Incyte, INCY, Form 4, RSU, Restricted Stock Units, Executive Compensation, Insider Transaction, Equity Grant